Atai Life Sciences N.V.
NASDAQ:ATAI
1.08 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0.314 | 0.233 | 20.376 | 0 | 0 |
| Cost of Revenue
| 0.319 | 0.168 | 0.047 | 0.024 | 0.006 |
| Gross Profit
| -0.005 | 0.065 | 20.329 | -0.024 | -0.006 |
| Gross Profit Ratio
| -0.016 | 0.279 | 0.998 | 0 | 0 |
| Reseach & Development Expenses
| 61.884 | 74.313 | 47.956 | 11.408 | 3.084 |
| General & Administrative Expenses
| 63.582 | 70.35 | 92.745 | 80.734 | 5.09 |
| Selling & Marketing Expenses
| -0 | 0 | 0 | 0 | 0 |
| SG&A
| 63.582 | 70.35 | 92.745 | 80.734 | 5.09 |
| Other Expenses
| -0.189 | 9.605 | -0.796 | -16.091 | 0.425 |
| Operating Expenses
| 125.466 | 144.663 | 140.701 | 92.142 | 8.174 |
| Operating Income
| -125.471 | -144.787 | -135.805 | -104.162 | 1.574 |
| Operating Income Ratio
| -399.589 | -621.403 | -6.665 | 0 | 0 |
| Total Other Income Expenses Net
| 86.185 | 9.605 | -0.796 | 2.349 | -19.048 |
| Income Before Tax
| -39.286 | -135.182 | -136.601 | -101.813 | -17.474 |
| Income Before Tax Ratio
| -125.115 | -580.18 | -6.704 | 0 | 0 |
| Income Tax Expense
| 1.016 | 6.229 | -3.989 | 0.305 | 0.002 |
| Net Income
| -40.224 | -141.411 | -132.612 | -102.118 | -17.476 |
| Net Income Ratio
| -128.102 | -606.914 | -6.508 | 0 | 0 |
| EPS
| -0.25 | -0.91 | -0.83 | -17.57 | -3.23 |
| EPS Diluted
| -0.25 | -0.91 | -0.83 | -17.57 | -3.23 |
| EBITDA
| -125.152 | -144.073 | -104.845 | -98.467 | 1.58 |
| EBITDA Ratio
| -398.573 | -618.339 | -5.146 | 0 | 0 |